The 11 most recent market catalysts affecting $PALI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 11, 2026
Corporate Catalyst
Neutral
Impact 65
Palisade Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Palisade Bio announced its third-quarter 2026 financial results and provided a business update focused on its lead product candidate, PALI-2108. The key development is the ongoing …
Oct 21, 2026
Corporate Catalyst
Bullish
Impact 65
Palisade Bio Presents New Data for PALI-2108 at UEG Week 2026
Palisade Bio presented new clinical data for PALI-2108, an oral PDE4 inhibitor prodrug, at UEG Week 2026, highlighting its potential for rapid endoscopic improvement in inflammator…
Oct 20, 2026
Corporate Catalyst
Bearish
Impact 65
Palisade Bio Announces Findings Presented At United European Gastroenterology Week; Five-Patient Phase 1B Crohn’s Disease Cohort Showed 47.5% Reduction In Mean Endoscopic Disease Activity And 58.8% Reduction In Mean Fecal Calprotectin After 14 Days; Phase 2b ASCENTRA-UC Study Is Enrolling; Phase 2a Crohn’s Disease Study Being Initiated
Palisade Bio announced the presentation of clinical and translational findings for PALI-2108 at United European Gastroenterology Week. The key takeaway is the positive Phase 1b dat…
Oct 13, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target
This 8-K filing discloses that HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a 'Buy' rating on Palisade Bio (PALI) and maintained a $7 price target. This is a posit…
Oct 9, 2026
Corporate Catalyst
Neutral
Impact 65
Raymond James Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $6
Raymond James analyst Thomas Deal has initiated coverage on Palisade Bio (PALI) with an 'Outperform' rating and a $6 price target. This is a positive development for Palisade Bio a…
Sep 28, 2026
Corporate Catalyst
Neutral
Impact 65
Palisade Bio To Present Four Presentations At United European Gastroenterology Week 2026 For Its PALI-2018 Program
Palisade Bio is announcing upcoming presentations for its lead drug candidate, PALI-2108, at a significant medical conference in October 2026. The key event is an oral presentation…
Sep 23, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target
This 8-K filing discloses that HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a 'Buy' rating on Palisade Bio (PALI) and maintained a $7 price target. This action sig…
Aug 10, 2026
Corporate Catalyst
Neutral
Impact 75
Proficient Auto Logistics Announces $75M Private Offering Of Convertible Senior Notes Due 2033 To Refinance Debt, Fund Capped Call; Settlement Expected August 13
This private offering of convertible senior notes by Proficient Auto Logistics (PALI) is a significant corporate finance event. The primary purpose is to refinance existing debt, w…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 65
Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative Colitis
Oppenheimer initiated coverage on Palisade Bio (PALI) with a 'Buy' rating and a price target of $8, citing the potential of its lead drug PALI-2108 in the inflammatory bowel diseas…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 75
Palisade Bio shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $8 price target.
This headline represents a significant corporate catalyst for Palisade Bio. Analyst initiation with a strong 'Outperform' rating and a substantial price target (implying significan…
Jul 23, 2026
Corporate Catalyst
Neutral
Impact 65
Oppenheimer Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $8
Oppenheimer's initiation of coverage on Palisade Bio with an 'Outperform' rating and an $8 price target is a significant event for the company. This provides a vote of confidence f…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.